Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

AMAG Pharmaceuticals to present at JP Morgan 28th Annual Healthcare Conference on 11th January, 2010 by providing a company update and discuss the company’s commercial launch of Feraheme.

AMAG Pharmaceuticals, Inc. is scheduled to present at the JP Morgan 28th Annual Healthcare Conference on 11th January, 2010.  Representing the company will be its President and CEO Brian Pereira, MD.  Dr. Pereira will provide a company update and discuss the company’s commercial launch of Feraheme.
 
Dr. Pereira will be doing his presentation on 11th January morning.
 
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its technology for the development and commercialization of a therapeutic iron compound to treat anemia, and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company has one product candidate, Feraheme (ferumoxytol injection), and two approved products, Feridex I.V. and GastroMARK. Feraheme is being developed for use as an intravenous (IV) iron replacement therapeutic agent for the treatment of iron deficiency anemia (IDA) and as a diagnostic agent for vascular enhanced magnetic resonance imaging ( MRI ) to assess peripheral arterial disease (PAD).

Source: AMAG

You can discuss about JP Morgan Healthcare conference and related topic in our Radiology & Healthcare IT Conferences Group.